With a probable approval for Novartis’s CTL019 (tisagenlecleucel) (OXB manufacture a key component) in both paediatric ALL and DLBCL on the horizon, Oxford BioMedica (OXB) is in position to crystallise a potentially significant revenue stream. Building on the original 2014 agreement with Novartis, the new commercial supply agreement for CTL019 includes $10m upfront and in excess of $90m in additional revenue over the next three years. Additionally, the company has refinanced its Oberlan
25 Jul 2017
CTL019 approval likely in pALL, ad-com positive
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
CTL019 approval likely in pALL, ad-com positive
- Published:
25 Jul 2017 -
Author:
Dr Daniel Wilkinson -
Pages:
7
With a probable approval for Novartis’s CTL019 (tisagenlecleucel) (OXB manufacture a key component) in both paediatric ALL and DLBCL on the horizon, Oxford BioMedica (OXB) is in position to crystallise a potentially significant revenue stream. Building on the original 2014 agreement with Novartis, the new commercial supply agreement for CTL019 includes $10m upfront and in excess of $90m in additional revenue over the next three years. Additionally, the company has refinanced its Oberlan